Akari Therapeutics Plc (AKTX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C8012)
◆英語タイトル:Akari Therapeutics Plc (AKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8012
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年10月
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Akari Therapeutics Plc (Akari), formerly Celsus Therapeutics Plc is a biopharmaceutical company that develops treatments for rare and orphan autoimmune and inflammatory diseases. The company offers coversin drugs that act on complement component-C5 that helps in preventing the release of C5a and formation of C5b – 9. The company’s pipeline products include paroxysmal nocturnal hemoglobinuria, Guillain Barre Syndrome and atypical hemolytic uremic syndrome. Akari pipeline products include Coversin, Coversin LA, LTB4+C5, LTB4, LTBA LA, and bioamine inhibitors. The company operates in Switzerland, Israel, the UK and the US. Akari is headquartered in New York City, New York, the US.

Akari Therapeutics Plc (AKTX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Licensing Agreements 12
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Equity Offering 13
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Acquisition 22
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc – Key Competitors 23
Akari Therapeutics Plc – Key Employees 24
Akari Therapeutics Plc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Sep 27, 2018: Akari announces second quarter 2018 financial results and business highlights 26
Aug 17, 2018: Akari announces first quarter 2018 financial results and update on its growing pipeline of phase II and phase III clinical trials 27
Mar 21, 2018: Akari Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Clinical Progress 29
Corporate Communications 31
May 08, 2018: Akari Therapeutics: Resignation of CEO 31
Jan 23, 2018: Akari Therapeutics Strengthens Board with Two Senior Industry Appointments 32
Aug 21, 2017: Akari Therapeutics Announces Appointment of David Horn Solomon as CEO 33
May 30, 2017: Akari Therapeutics Announces Resignation of CEO 34
Product Approvals 35
Mar 30, 2017: Akari Therapeutics Announces FDA Fast Track Designation For Coversin 35
Clinical Trials 36
Jun 15, 2018: Akari Therapeutics to Present Poster at the 23rd Congress of the European Hematology Association 36
Feb 06, 2018: Akari Therapeutics Announces Completion of Phase II COBALT Trial of Coversin in Patients with PNH and Further Progress of Clinical Trials 37
Dec 08, 2017: Akari Therapeutics Announces Phase II COBALT trial of Coversin in Patients with PNH Met the Primary Endpoint 38
Oct 11, 2017: Akari Therapeutics Announces Further Clinical Progress 39
Sep 21, 2017: Akari Therapeutics Announces Regulatory Progress Following FDA Meeting 40
Apr 27, 2017: Akari Therapeutics Announces Edisons Withdrawal of Edison Report titled “Akari’s Coversin matches Soliris in Phase II” 41
Apr 24, 2017: Akari Therapeutics Demonstrates Positive Response with Coversin in Ongoing Phase 2 PNH Trial and in Additional Clinical Targets 42
Jan 03, 2017: Akari Therapeutics Announces FDA Allowance of IND for Clinical Development of Coversin in PNH 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Deals By Therapy Area, 2012 to YTD 2018 9
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Morria BioPharma Enters Into Co-Development Agreement With SCYNEXIS For MRX-4 11
Akari Therapeutics Enters into Licensing Agreement with XL-protein for Coversin 12
Akari Therapeutics Prices Public Offering of American Depositary Shares for USD17.4 Million 13
Celsus Therapeutics Raises USD75 Million in Private Placement of ADS 15
Celsus Therapeutics Completes Public Offering Of American Depositary Shares For US$8 Million 17
Celsus Therapeutics Completes Private Placement Of Shares For US$12.5 Million 19
Morria Biopharma Completes Private Placement Of Shares For US$0.8 Million 20
Morria Biopharma Completes Private Placement Of Units For US$1.5 Million 21
Celsus Therapeutics Acquires Volution Immuno Pharma 22
Akari Therapeutics Plc, Key Competitors 23
Akari Therapeutics Plc, Key Employees 24
Akari Therapeutics Plc, Other Locations 25
Akari Therapeutics Plc, Subsidiaries 25

List of Figures
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akari Therapeutics Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Akari Therapeutics Plc (AKTX):製薬・医療:M&Aディール及び事業提携情報(Akari Therapeutics Plc (AKTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆